GlycoMimetics (GLYC) News Today → Who are Nvidia’s New Silent Partners? (From Weiss Ratings) (Ad) Free GLYC Stock Alerts $0.27 0.00 (0.00%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 28 at 9:53 AM | finance.yahoo.comPipeline Moves: Phase III AML trial fails to meet primary endpointMay 22, 2024 | americanbankingnews.comGlycoMimetics (NASDAQ:GLYC) Coverage Initiated by Analysts at StockNews.comMay 22, 2024 | americanbankingnews.comGlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.comMay 10, 2024 | msn.comGlycoMimetics GAAP EPS of -$0.17 in-lineMay 9, 2024 | msn.comGlycoMimetics Q1 2024 Earnings PreviewMay 8, 2024 | markets.businessinsider.comSell Rating on Lyra Therapeutics Amid Phase 3 Study Failure and Funding ConcernsMay 7, 2024 | msn.comHC Wainwright & Co. Downgrades GlycoMimetics (GLYC)May 6, 2024 | msn.comGlycoMimetics' Uproleselan Flunks In Late Stage Leukemia Study, Shares SinkMay 6, 2024 | markets.businessinsider.comWhy Is GlycoMimetics Stock Falling In Pre-market?May 6, 2024 | marketwatch.comGlycoMimetics Shares Drop After Leukemia Treatment Trial Fails to Meet Primary EndpointMay 6, 2024 | businesswire.comGlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)April 28, 2024 | finance.yahoo.comWe're Keeping An Eye On GlycoMimetics' (NASDAQ:GLYC) Cash Burn RateApril 27, 2024 | finance.yahoo.comGlycoMimetics, Inc. (GLYC)April 25, 2024 | businesswire.comGlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024April 16, 2024 | marketbeat.comGlycoMimetics, Inc. (NASDAQ:GLYC) Sees Significant Growth in Short InterestGlycoMimetics, Inc. (NASDAQ:GLYC - Get Free Report) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 1,590,000 shares, a growth of 6.7% from the March 15th total of 1,490,000 shares. Based on an average daily trading volume, of 367,100 shares, the short-interest ratio is presently 4.3 days.April 15, 2024 | money.usnews.comGlycoMimetics IncApril 1, 2024 | finance.yahoo.comLoss-Making GlycoMimetics, Inc. (NASDAQ:GLYC) Expected To Breakeven In The Medium-TermMarch 28, 2024 | finance.yahoo.comGlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | marketbeat.comGlycoMimetics, Inc. Expected to Post FY2026 Earnings of $0.14 Per Share (NASDAQ:GLYC)GlycoMimetics, Inc. (NASDAQ:GLYC - Free Report) - Research analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for GlycoMimetics in a note issued to investors on Wednesday, March 27th. HC Wainwright analyst E. White anticipates that the biotechnology company will postMarch 28, 2024 | markets.businessinsider.comPositive Outlook for GlycoMimetics: Buy Rating Affirmed Amid Anticipated Pivotal Trial Results and Strategic Growth InitiativesMarch 28, 2024 | finance.yahoo.comQ4 2023 GlycoMimetics Inc Earnings CallMarch 27, 2024 | markets.businessinsider.comBuy Rating on GlycoMimetics Backed by Strong Financials and Promising Phase 3 Trial of UproleselanMarch 27, 2024 | markets.businessinsider.comBuy Recommendation for GlycoMimetics Based on Promising Upro Drug Prospects and Strong PipelineMarch 27, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for GlycoMimetics (NASDAQ:GLYC)HC Wainwright reiterated a "buy" rating and issued a $8.00 price objective on shares of GlycoMimetics in a report on Wednesday.March 27, 2024 | investorplace.comGLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023March 27, 2024 | sfgate.comGlycoMimetics: Q4 Earnings SnapshotMarch 27, 2024 | finance.yahoo.comGlycoMimetics Inc (GLYC) Posts Quarterly Loss, Aligns with Analyst ProjectionsMarch 27, 2024 | businesswire.comGlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023March 21, 2024 | seekingalpha.comGlycoMimetics Can Become A Game Changer In Blood CancersMarch 19, 2024 | marketbeat.comGlycoMimetics, Inc. (NASDAQ:GLYC) Short Interest Up 9.1% in FebruaryGlycoMimetics, Inc. (NASDAQ:GLYC - Get Free Report) was the recipient of a significant growth in short interest during the month of February. As of February 29th, there was short interest totalling 1,560,000 shares, a growth of 9.1% from the February 14th total of 1,430,000 shares. Based on an average daily trading volume, of 336,300 shares, the days-to-cover ratio is currently 4.6 days.March 16, 2024 | finance.yahoo.comGLYC Apr 2024 2.500 callMarch 16, 2024 | finance.yahoo.comGLYC Apr 2024 2.500 putMarch 16, 2024 | markets.businessinsider.comGlycoMimetics Inc hosts conference call for investorsMarch 16, 2024 | finance.yahoo.comGLYC Apr 2024 5.000 callMarch 14, 2024 | marketbeat.comGlycoMimetics (NASDAQ:GLYC) Downgraded by StockNews.com to SellStockNews.com lowered GlycoMimetics from a "hold" rating to a "sell" rating in a research report on Thursday.March 14, 2024 | msn.comImmuneering cancer drug shows initial clinical activity in early-stage trialMarch 13, 2024 | barrons.comPalatin Technologies Inc.March 13, 2024 | businesswire.comGlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024March 10, 2024 | morningstar.comGlycoMimetics Inc GLYCMarch 4, 2024 | finance.yahoo.comPositive Signs As Multiple Insiders Buy GlycoMimetics StockFebruary 28, 2024 | marketbeat.comAcadian Asset Management LLC Sells 305,605 Shares of GlycoMimetics, Inc. (NASDAQ:GLYC)Acadian Asset Management LLC reduced its holdings in shares of GlycoMimetics, Inc. (NASDAQ:GLYC - Free Report) by 26.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 844,051 shares of the biotechnology company'sFebruary 26, 2024 | finance.yahoo.comGlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care ConferenceFebruary 26, 2024 | businesswire.comGlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care ConferenceFebruary 23, 2024 | finance.yahoo.comGlycoMimetics, Inc. (GKO.F)February 12, 2024 | finance.yahoo.comGlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)January 30, 2024 | seekingalpha.comGlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be RealJanuary 5, 2024 | benzinga.comGlycoMimetics Stock (NASDAQ:GLYC), Analyst Ratings, Price Targets, PredictionsJanuary 4, 2024 | markets.businessinsider.comGlycoMimetics' GMI-1687 Meets Primary Goal In Phase 1a StudyJanuary 4, 2024 | finance.yahoo.comGlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687December 30, 2023 | benzinga.comGlycoMimetics Stock (NASDAQ:GLYC) Dividends: History, Yield and Dates Get GlycoMimetics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter. Email Address Who are Nvidia’s New Silent Partners? (Ad)Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself. I call these Nvidia’s “Silent Partners.” GLYC Media Mentions By Week GLYC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GLYC News Sentiment▼0.830.87▲Average Medical News Sentiment GLYC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GLYC Articles This Week▼61▲GLYC Articles Average Week Get GlycoMimetics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Talphera News Tonix Pharmaceuticals News Orgenesis News Aytu BioPharma News NeuroSense Therapeutics News Minerva Neurosciences News KALA BIO News Galecto News VBI Vaccines News BioVie News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GLYC) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersWARNING about the death of the U.S. dollar…Colonial MetalsDigitizing the $11T commodities sector with one tiny stockResource Stock DigestTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsElon’s New Device is About to Shock the WorldInvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
